Developer docs
API playgroundTry for free, no card

Search company profiles

Progentec Diagnostics

Full company profile

uuid0002xiq

Namestring
Progentec Diagnostics
Legal namestring
Progentec Diagnostics, Inc.
Websiteurl
progentec.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOklahoma City, United States
HQ citystring
Oklahoma City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lupus diagnostic testing, proteomics biomarker tests, autoimmune disease management, digital health platform, clinical laboratory services
Industry6 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code4 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Autoimmune Disease Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Laboratory Diagnostic Testing
TypeOne Time License
Description

Revenue from proprietary blood biomarker tests (aiSLE DX FRI and aiSLE DX DAI) sold to rheumatologists and healthcare systems. Tests are billed via PLA codes (0446U, 0447U) at $840.65 Medicare rate when covered. Distribution through Mayo Clinic Laboratories and direct ordering.

progentec.com
2Digital Health Platform Services
TypeSubscription Recurring
Description

aiSLE MGMT platform combining laboratory tests with digital tools, health coaching, and remote monitoring services for comprehensive lupus management.

progentec.com
3Clinical Research Services
TypeProfessional Services
Description

Decentralized clinical study technologies and study management services provided to pharmaceutical companies and research institutions including GSK partnership.

progentec.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1Medicare-covered testing at $840.65 per test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

PLA codes 0446U (FRI) and 0447U (DAI) assigned by CMS with Medicare payment rate of $840.65 per test when covered, effective January 1, 2025.

progentec.com
2aiSLE MGMT with aiSLE Access For All financial support
ModelSubscriptionBilling cadenceMonthly
Notes

Patient out-of-pocket costs: $0 for households under $52,400; $26 for households under $85,150; $50 for households $85,151+. Not available for federal/state-funded insurance (Medicare, Medicaid, VA, TriCare, IHS).

progentec.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1aiSLE MGMT
Description

A lupus management platform combining aiSLE DX laboratory tests with AutoimmuneCorner mobile app and health coaching for proactive lupus care.

progentec.com
+4 more records
Core offering1 text field

Progentec Diagnostics develops and commercializes proprietary blood-based proteomics biomarker tests (the aiSLE DX Flare Risk Index and Disease Activity Index) that analyze immune mediators to predict lupus flares up to 12 weeks in advance and objectively measure current SLE disease activity. The company complements these laboratory tests with a digital health ecosystem—the aiSLE MGMT platform, AutoimmuneCorner mobile app with wearable integration, and LupusCorner Research decentralized clinical study platform—offered to rheumatologists, healthcare systems, and pharmaceutical sponsors through Mayo Clinic Laboratories and direct ordering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Patients with positive aiSLE DX Flare Risk Index score are almost 5 times more likely to flare (OR approaches 5.0, p=0.0015)
+2 more records
Product overview1 text field

Progentec Diagnostics operates as a platform-plus-modules company offering both proprietary laboratory biomarker tests and a digital health ecosystem for autoimmune disease management. The core aiSLE DX family of tests includes the Flare Risk Index (FRI) and Disease Activity Index (DAI), both commercially available blood tests analyzing immune mediators to predict and measure lupus disease activity. These tests are delivered through Mayo Clinic Laboratories and directly via Progentec's CLIA-certified lab. The aiSLE MGMT platform integrates these laboratory results with the AutoimmuneCorner mobile app (featuring health coaching and Withings smartwatch integration), LupusCorner patient engagement tools, and LupusCorner Research for decentralized clinical studies. The pipeline includes aiSLE DX Classification for lupus diagnosis, and the aiMS DX suite of tests for multiple sclerosis management including relapse prediction, disease activity measurement, and interferon treatment response monitoring.

Product and service4 records
1aiSLE DX Flare Risk Index (FRI)
CategoryDiagnostic Laboratory Test
Description

A proprietary blood-based proteomics test powered by LiquidFlareRisk technology that analyzes 11 immune mediators (cytokines, chemokines, and soluble receptors) to predict the likelihood of an SLE disease flare within 12 weeks, with an odds ratio approaching 5.0 (p=0.0015). Validated in European American, African American, and Native American cohorts; ordered by rheumatologists and reimbursed under PLA code 0446U at $840.65. Distributed through Mayo Clinic Laboratories and direct practice ordering.

2aiSLE DX Disease Activity Index (DAI)
CategoryDiagnostic Laboratory Test
Description

A proprietary blood-based biomarker test powered by LiquidDiseaseActivity technology that provides an objective measure of current SLE disease activity, distinguishing active versus low/quiescent disease and calibrated against hybrid SLEDAI scoring. Reimbursed under PLA code 0447U at $840.65; ordered by rheumatologists through Mayo Clinic Laboratories or directly from Progentec.

3aiSLE MGMT Care Platform
CategoryDigital Health Management Platform
Description

A comprehensive lupus management platform combining aiSLE DX laboratory tests with the AutoimmuneCorner mobile app (symptom/flare tracking, Withings Steel HR wearable integration, validated PROs) and health coaching services to deliver proactive lupus care. Offered as a subscription with tiered patient co-pays under the aiSLE Access For All program ($0, $26, or $50 based on household income).

4LupusCorner Research
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-07
Description

Strategic collaboration to bring Progentec's proprietary biomarker blood tests for autoimmune disease management to market. Mayo Clinic Laboratories serves as the exclusive reference laboratory distributor for aiSLE DX Flare Risk Index and aiSLE DX Disease Activity Index tests, available to Mayo's network of 3,400+ healthcare organizations globally. Tests became available April 25, 2024.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-08
Description

Research collaboration to assess proteomics and digital health tools for lupus (SLE) care. Includes the PROACTIVE study (launched March 2023) for early lupus screening and identification of individuals at risk. Joint development of lupus diagnostic and monitoring solutions.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-07-01
Description

Licensing agreement for multiple sclerosis technologies developed at Stanford University. Covers laboratory technologies related to MS diagnosis and monitoring.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-30
Description

Merger with Karate Health, maker of digital technologies for chronic health conditions, to create comprehensive autoimmune disease management platform combining laboratory testing and digital tools.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2015-09-30
Description

Collaboration to commercialize autoimmune diagnostic technologies developed at OMRF. Includes licensing of lupus biomarker technology from Dr. Judith James's research. OMRF scientists (Dr. Melissa Munroe, Dr. Judith James) involved in product development.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Supports aiSLE DX Flare Risk Index testing access for patients with lupus (SLE), helping expand patient access to the test.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Exagen develops AVISE CTD and AVISE SLE diagnostic tests for autoimmune diseases including lupus — the closest direct competitor to Progentec's aiSLE DX franchise. Both companies serve rheumatologists with blood-based biomarker tests for SLE diagnosis, monitoring, and management.

2Inova Diagnostics (Werfen)
TypeDirect peer
Description

Inova Diagnostics, part of Werfen, is a global leader in autoimmune disease diagnostics with a broad menu of specialty immunology assays and biomarker tests. Directly competes with Progentec in autoimmune serology and proteomics-based testing.

TypeDirect peer
Description

Sengenics provides proteomics-based biomarker discovery and autoimmune diagnostics using high-content protein array technology. Directly comparable to Progentec's proteomics + autoimmune disease focus.

TypeDirect peer
Description

Euroimmun, part of Revvity/PerkinElmer, is a leading autoimmune diagnostics company offering a comprehensive portfolio of specialty immunology tests — a direct competitor in autoimmune lab testing serving rheumatology.

TypeBroad incumbent
Description

Thermo Fisher supplies the proteomics instruments (e.g., mass spectrometry, multiplex immunoassay platforms) and provides specialty lab services used in autoimmune biomarker work. A broad incumbent with overlapping capabilities but not specializing in SLE.

TypeBroad incumbent
Description

Bio-Techne manufactures proteomics reagents and assay kits (including the ProteinSimple Ella microfluidic platform Progentec uses) and offers tools for cytokine/chemokine biomarker discovery — comparable as a proteomics-enabling incumbent.

TypeBroad incumbent
Description

LabCorp is one of the largest clinical laboratory networks in the US offering autoimmune and rheumatology testing panels — a broad incumbent competitor whose reach could compete with Progentec's specialty tests if validated into routine panels.

TypeBroad incumbent
Description

Quest Diagnostics is the largest US clinical lab company, offering specialty immunology and autoimmune test panels through its reference lab network. Comparable as a broad incumbent with overlapping capabilities.

TypeEmerging player
Description

Adaptive Biotechnologies uses immune receptor sequencing and immune profiling to develop diagnostic and monitoring tools — adjacent technology with comparable focus on immune-mediated disease biomarkers, though commercially more established.

TypeRegional player
Description

Myriad Genetics offers genetic and molecular diagnostic tests in autoimmune and rheumatology-adjacent indications. Comparable as a specialty diagnostics company operating primarily in the US with a similar profile of focused molecular tests.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Progentec Diagnostics

Autoimmune Disease Diagnosticsprogentec.com

Progentec Diagnostics firmographics

Firmographics
Name
Progentec Diagnostics
Legal name
Progentec Diagnostics, Inc.
Website
https://progentec.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Progentec Diagnostics industry classification

Industry
Product category
Autoimmune Disease Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Lupus diagnostic testing
  • Proteomics biomarker tests
  • Autoimmune disease management
  • Digital health platform
  • Clinical laboratory services

Where Progentec Diagnostics is headquartered

Location

Headquarters

HQ city
Oklahoma City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Progentec Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Laboratory Diagnostic Testing: Revenue from proprietary blood biomarker tests (aiSLE DX FRI and aiSLE DX DAI) sold to rheumatologists and healthcare systems. Tests are billed via PLA codes (0446U, 0447U) at $840.65 Medicare rate when covered. Distribution through Mayo Clinic Laboratories and direct ordering.
  2. Digital Health Platform Services: aiSLE MGMT platform combining laboratory tests with digital tools, health coaching, and remote monitoring services for comprehensive lupus management.
  3. Clinical Research Services: Decentralized clinical study technologies and study management services provided to pharmaceutical companies and research institutions including GSK partnership.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goMedicare-covered testing at $840.65 per test
SubscriptionMonthlyaiSLE MGMT with aiSLE Access For All financial support

Go-to-market motion3 records

Distribution channels2 records

Marketing channels8 records

Progentec Diagnostics product offering

Product offering

Core offering

Progentec Diagnostics develops and commercializes proprietary blood-based proteomics biomarker tests (the aiSLE DX Flare Risk Index and Disease Activity Index) that analyze immune mediators to predict lupus flares up to 12 weeks in advance and objectively measure current SLE disease activity. The company complements these laboratory tests with a digital health ecosystem—the aiSLE MGMT platform, AutoimmuneCorner mobile app with wearable integration, and LupusCorner Research decentralized clinical study platform—offered to rheumatologists, healthcare systems, and pharmaceutical sponsors through Mayo Clinic Laboratories and direct ordering.

Product overview

Progentec Diagnostics operates as a platform-plus-modules company offering both proprietary laboratory biomarker tests and a digital health ecosystem for autoimmune disease management. The core aiSLE DX family of tests includes the Flare Risk Index (FRI) and Disease Activity Index (DAI), both commercially available blood tests analyzing immune mediators to predict and measure lupus disease activity. These tests are delivered through Mayo Clinic Laboratories and directly via Progentec's CLIA-certified lab. The aiSLE MGMT platform integrates these laboratory results with the AutoimmuneCorner mobile app (featuring health coaching and Withings smartwatch integration), LupusCorner patient engagement tools, and LupusCorner Research for decentralized clinical studies. The pipeline includes aiSLE DX Classification for lupus diagnosis, and the aiMS DX suite of tests for multiple sclerosis management including relapse prediction, disease activity measurement, and interferon treatment response monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • aiSLE MGMT: A lupus management platform combining aiSLE DX laboratory tests with AutoimmuneCorner mobile app and health coaching for proactive lupus care.
  • LupusCorner
  • AutoimmuneCorner
  • aiSLE DX
  • LupusCorner Research

Products and services

  • aiSLE DX Flare Risk Index (FRI) A proprietary blood-based proteomics test powered by LiquidFlareRisk technology that analyzes 11 immune mediators (cytokines, chemokines, and soluble receptors) to predict the likelihood of an SLE disease flare within 12 weeks, with an odds ratio approaching 5.0 (p=0.0015). Validated in European American, African American, and Native American cohorts; ordered by rheumatologists and reimbursed under PLA code 0446U at $840.65. Distributed through Mayo Clinic Laboratories and direct practice ordering.
  • aiSLE DX Disease Activity Index (DAI) A proprietary blood-based biomarker test powered by LiquidDiseaseActivity technology that provides an objective measure of current SLE disease activity, distinguishing active versus low/quiescent disease and calibrated against hybrid SLEDAI scoring. Reimbursed under PLA code 0447U at $840.65; ordered by rheumatologists through Mayo Clinic Laboratories or directly from Progentec.
  • aiSLE MGMT Care Platform A comprehensive lupus management platform combining aiSLE DX laboratory tests with the AutoimmuneCorner mobile app (symptom/flare tracking, Withings Steel HR wearable integration, validated PROs) and health coaching services to deliver proactive lupus care. Offered as a subscription with tiered patient co-pays under the aiSLE Access For All program ($0, $26, or $50 based on household income).
  • LupusCorner Research

Quantifiable outcome

  • Patients with positive aiSLE DX Flare Risk Index score are almost 5 times more likely to flare (OR approaches 5.0, p=0.0015)
  • +2 more outcomes

Companies that use Progentec Diagnostics

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Progentec Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability11 records

Feature7 records

Progentec Diagnostics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

  • Mayo Clinic LaboratoriesflagshipChannel Partner/ Reseller/ Distributor · 7 November 2023Strategic collaboration to bring Progentec's proprietary biomarker blood tests for autoimmune disease management to market. Mayo Clinic Laboratories serves as the exclusive reference laboratory distributor for aiSLE DX Flare Risk Index and aiSLE DX Disease Activity Index tests, available to Mayo's network of 3,400+ healthcare organizations globally. Tests became available April 25, 2024.
  • GSKcoreStrategic or Co-development Partner · 8 June 2021Research collaboration to assess proteomics and digital health tools for lupus (SLE) care. Includes the PROACTIVE study (launched March 2023) for early lupus screening and identification of individuals at risk. Joint development of lupus diagnostic and monitoring solutions.
  • Stanford UniversitycoreTechnology or Integration · 1 July 2020Licensing agreement for multiple sclerosis technologies developed at Stanford University. Covers laboratory technologies related to MS diagnosis and monitoring.
  • Karate HealthcoreStrategic or Co-development Partner · 30 July 2019Merger with Karate Health, maker of digital technologies for chronic health conditions, to create comprehensive autoimmune disease management platform combining laboratory testing and digital tools.
  • Oklahoma Medical Research Foundation (OMRF)coreTechnology or Integration · 30 September 2015Collaboration to commercialize autoimmune diagnostic technologies developed at OMRF. Includes licensing of lupus biomarker technology from Dr. Judith James's research. OMRF scientists (Dr. Melissa Munroe, Dr. Judith James) involved in product development.
  • BendcareminorGTM or Marketing PartnerSupports aiSLE DX Flare Risk Index testing access for patients with lupus (SLE), helping expand patient access to the test.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Progentec Diagnostics competitors and assessment

Company assessment

Direct peers

  • Exagen Inc. Exagen develops AVISE CTD and AVISE SLE diagnostic tests for autoimmune diseases including lupus — the closest direct competitor to Progentec's aiSLE DX franchise. Both companies serve rheumatologists with blood-based biomarker tests for SLE diagnosis, monitoring, and management.
  • Inova Diagnostics (Werfen): Inova Diagnostics, part of Werfen, is a global leader in autoimmune disease diagnostics with a broad menu of specialty immunology assays and biomarker tests. Directly competes with Progentec in autoimmune serology and proteomics-based testing.
  • Sengenics: Sengenics provides proteomics-based biomarker discovery and autoimmune diagnostics using high-content protein array technology. Directly comparable to Progentec's proteomics + autoimmune disease focus.
  • Euroimmun (PerkinElmer): Euroimmun, part of Revvity/PerkinElmer, is a leading autoimmune diagnostics company offering a comprehensive portfolio of specialty immunology tests — a direct competitor in autoimmune lab testing serving rheumatology.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher supplies the proteomics instruments (e.g., mass spectrometry, multiplex immunoassay platforms) and provides specialty lab services used in autoimmune biomarker work. A broad incumbent with overlapping capabilities but not specializing in SLE.
  • Bio-Techne: Bio-Techne manufactures proteomics reagents and assay kits (including the ProteinSimple Ella microfluidic platform Progentec uses) and offers tools for cytokine/chemokine biomarker discovery — comparable as a proteomics-enabling incumbent.
  • Laboratory Corporation of America (LabCorp): LabCorp is one of the largest clinical laboratory networks in the US offering autoimmune and rheumatology testing panels — a broad incumbent competitor whose reach could compete with Progentec's specialty tests if validated into routine panels.
  • Quest Diagnostics: Quest Diagnostics is the largest US clinical lab company, offering specialty immunology and autoimmune test panels through its reference lab network. Comparable as a broad incumbent with overlapping capabilities.

Emerging players

  • Adaptive Biotechnologies: Adaptive Biotechnologies uses immune receptor sequencing and immune profiling to develop diagnostic and monitoring tools — adjacent technology with comparable focus on immune-mediated disease biomarkers, though commercially more established.

Regional players

  • Myriad Genetics: Myriad Genetics offers genetic and molecular diagnostic tests in autoimmune and rheumatology-adjacent indications. Comparable as a specialty diagnostics company operating primarily in the US with a similar profile of focused molecular tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Progentec Diagnostics social profiles

Digital presence

Progentec Diagnostics compliance and trust

Trust signal

Compliance3 records

Progentec Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Progentec Diagnostics leadership team

Management profile

Number of profiles

Profiles11 records

Progentec Diagnostics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Progentec Diagnostics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Progentec Diagnostics

What does Progentec Diagnostics do?

Progentec Diagnostics develops and commercializes proprietary blood-based proteomics biomarker tests (the aiSLE DX Flare Risk Index and Disease Activity Index) that analyze immune mediators to predict lupus flares up to 12 weeks in advance and objectively measure current SLE disease activity. The company complements these laboratory tests with a digital health ecosystem—the aiSLE MGMT platform, AutoimmuneCorner mobile app with wearable integration, and LupusCorner Research decentralized clinical study platform—offered to rheumatologists, healthcare systems, and pharmaceutical sponsors through Mayo Clinic Laboratories and direct ordering.

Is Progentec Diagnostics a public or private company?

Progentec Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Progentec Diagnostics founded?

Progentec Diagnostics was founded in 2015. It employs 11 to 50 people.

Where is Progentec Diagnostics based?

Progentec Diagnostics is headquartered in Oklahoma City, United States, in the North America region.

How does Progentec Diagnostics make money?

Three revenue lines are on record. Laboratory Diagnostic Testing is the primary driver. The others are digital Health Platform Services and clinical Research Services.

Who are Progentec Diagnostics's main competitors?

Direct peers on record are Exagen Inc., Inova Diagnostics (Werfen), Sengenics and Euroimmun (PerkinElmer). Broad incumbents are Thermo Fisher Scientific, Bio-Techne, Laboratory Corporation of America (LabCorp) and Quest Diagnostics. Adaptive Biotechnologies is listed as an emerging player. Myriad Genetics is listed as a regional player.

Does Progentec Diagnostics have an API?

No public API is recorded for Progentec Diagnostics.

What industry is Progentec Diagnostics in?

Progentec Diagnostics's product category is Autoimmune Disease Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceProgentec Diagnostics Advances Ability to Determine Lupus Risk with New Research and OCAST GrantProgentec Diagnostics published a study introducing a Lupus Classification Risk Immune Index (L-CRI) that identifies at-risk individuals months to years before clinical lupus diagnosis. The company also received an OCAST Industry Innovation Grant to develop and validate the test.The Journal RecordProgentec Diagnostics advances lupus risk test with new grantProgentec Diagnostics published a study on a lupus classification risk blood test and received an Oklahoma state grant to further develop it. The test uses an immune-based index to identify at-risk individuals before clinical diagnosis. The grant will support clinical validation of the test.PR NewswireProgentec Diagnostics Advances Ability to Determine Lupus Risk with New Research and OCAST GrantProgentec Diagnostics announced new peer-reviewed research published in Lupus Science & Medicine that introduces a Lupus Classification Risk Immune Index (L-CRI), a blood test designed to identify individuals at risk of developing systemic lupus erythematosus months to years before clinical diagnosis. The research was led by Progentec's Chief Scientific Officer in collaboration with the Oklahoma Medical Research Foundation. The company has also been awarded an OCAST Industry Innovation Grant to support further development and clinical validation of the lupus classification risk test.Grand View ResearchU.S. Autoimmune Disease Diagnostics Market To Reach $3.01Bn By 2030The U.S. autoimmune disease diagnostics market is projected to reach $3.01 billion by 2030, growing at a 5.2% CAGR from 2024 to 2030. Localized diagnostics held a 66% share in 2023, and antinuclear antibody tests led the test-type segment. A partnership between Progentec Diagnostics and Mayo Clinic Laboratories was announced in November 2023.PR NewswireProgentec Diagnostics' Proprietary aiSLE® DX FRI and DAI Lupus Biomarker Tests Receive PLA Codes and Final Payment Determination from the Centers of Medicare and Medicaid ServicesProgentec Diagnostics received final payment determinations from the Centers for Medicare and Medicaid Services (CMS) for its aiSLE DX FRI and aiSLE DX DAI biomarker tests, effective January 1, 2025. CMS established PLA codes for these tests with a reimbursement rate of $840.65 per claim when covered. This approval facilitates increased patient access to tests that identify lupus flare risks and measure disease activity, which are administered through Mayo Clinic Laboratories.ProgentecNews — Progentec Diagnostics, Inc.The Centers for Medicare and Medicaid Services (CMS) has issued final payment determinations for Progentec Diagnostics' proprietary aiSLE DX FRI and DAI lupus biomarker tests, assigning PLA codes (0446U and 0447U) with a Medicare payment rate of $840.65 per test when covered, effective January 1, 2025. The company states this milestone will help establish a route to increased patient access and test adoption, with the tests made available through Mayo Clinic Laboratories. The aiSLE DX FRI identifies a lupus patient's future risk of flare, while aiSLE DX DAI measures disease activity levels in patients.YahooU.S. Autoimmune Disease Diagnostics (Systemic, Localized) Market Size, Share & Trends Analysis Report 2024-2030The U.S. autoimmune disease diagnostics market is projected to reach $3.01 billion by 2030, growing at a 5.2% CAGR from 2024 to 2030. Localized diagnostics held a 66% share in 2023, and antinuclear antibody tests led the test-type segment. A partnership between Progentec Diagnostics and Mayo Clinic Laboratories was announced in November 2023 to commercialize biomarker blood tests.Clinical Lab ProductsMayo Clinic Labs and Progentec Collaborate on Advanced Biomarker Tests for Autoimmune DiseasesMayo Clinic Laboratories and Progentec Diagnostics announced a strategic collaboration to commercialize Progentec’s proprietary biomarker blood tests for the proactive management of autoimmune diseases. As part of this partnership, Mary Jo Williamson from Mayo Clinic Laboratories joined Progentec's board of directors to facilitate test adoption and guidance.PR NewswireProgentec Launches PROACTIVE™ - A Novel Approach to Screen and Diagnose Lupus at an Early StageProgentec Diagnostics has launched PROACTIVE, a collaborative study with GSK designed to identify individuals at risk of developing lupus and guide them through a virtual diagnostic journey comprising online assessments, biomarker tests, and virtual specialist consultations. The study aims to provide a convenient and accessible approach to early lupus detection, addressing the challenge of unexplained symptoms that many patients experience. Lupus is a chronic autoimmune disease affecting millions of people worldwide, making early diagnosis crucial for effective treatment and management.PR NewswireGlobal Autoimmune Disease Diagnostics Market Report 2021: Market is Expected to Reach $7.84 Bn by 2026 - Rise in Online Diagnostic Centres and Laboratory AutomationResearch and Markets published a report forecasting the global autoimmune disease diagnostics market to grow from USD 4.98 billion in 2021 to USD 7.84 billion by 2026, driven by rising disease prevalence and healthcare expenditure. The report highlights key market players including Thermo Fisher Scientific, Siemens AG, Abbott Laboratories, and Progentec Diagnostics.